Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001368103 | SCV001564481 | uncertain significance | not provided | 2023-05-16 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant  is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 1058914). This variant has not been reported in the literature in individuals affected with MSH3-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.003%). This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 1031 of the MSH3 protein (p.Gly1031Ala). |
Sema4, |
RCV002256750 | SCV002536496 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-03-18 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV002256750 | SCV002606327 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-10-04 | criteria provided, single submitter | clinical testing | The p.G1031A variant (also known as c.3092G>C), located in coding exon 22 of the MSH3 gene, results from a G to C substitution at nucleotide position 3092. The glycine at codon 1031 is replaced by alanine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Baylor Genetics | RCV004570901 | SCV005053603 | uncertain significance | Endometrial carcinoma | 2024-03-04 | criteria provided, single submitter | clinical testing |